GlobalData on MSN20h
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients
The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.
MedPage Today on MSN15h
Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular Dystrophy
A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
Sarepta Therapeutics (NASDAQ:SRPT) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...
Patient dies following muscular dystrophy gene therapy, Sarepta reports
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
Ticker: Sarepta reports death in drug trial; Google makes $32B cybersecurity deal
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy.
News and Sentinel6h
Patient dies following muscular dystrophy gene therapy
Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting more than 25%. The young man died of acute ...
Investor's Business Daily on MSN17h
Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.
Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.
Muscular Dystrophy News55m
Sarepta reports death of DMD patient given gene therapy, Elevidys
A young man with Duchenne MD and treated with Elevidys has died of acute liver failure, Sarepta reports; it's working with ...